（编辑 姚尧） 证券日报网讯 1月28日，爱美客在互动平台回答投资者提问时表示，公司新品的终端销售、复购率、医 院进货数据等涉及商业和具体经营数据，公司未有单独的披露数据。公司严格按照法律法规的要求履行 信披义务。 ...

Market Overview - The medical beauty sector experienced a decline of 1.57% on January 28, with Jinbo Biological leading the drop [1] - The Shanghai Composite Index closed at 4151.24, up 0.27%, while the Shenzhen Component Index closed at 14342.9, up 0.09% [1] Stock Performance - Key stocks in the medical beauty sector showed the following performance: - *ST Meigu closed at 3.17, down 0.63% with a trading volume of 66,700 shares and a turnover of 21.20 million yuan [1] - Aimeike closed at 138.12, down 1.56% with a trading volume of 29,800 shares and a turnover of 413 million yuan [1] - Huaxi Biological closed at 45.64, down 1.70% with a trading volume of 28,800 shares and a turnover of 13.20 million yuan [1] - Jinbo Biological closed at 223.85, down 1.97% with a trading volume of 7,323 shares and a turnover of 165 million yuan [1] Capital Flow - The medical beauty sector saw a net outflow of 49.81 million yuan from main funds, while retail investors had a net inflow of 55.20 million yuan [1] - Detailed capital flow for key stocks includes: - *ST Meigu: Main funds net outflow of 1.98 million yuan, retail net inflow of 1.61 million yuan [2] - Huaxi Biological: Main funds net outflow of 9.06 million yuan, retail net inflow of 3.16 million yuan [2] - Jinbo Biological: Main funds net outflow of 25.03 million yuan, retail net inflow of 0.38 million yuan [2] - Aimeike: Main funds net outflow of 38.77 million yuan, retail net inflow of 50.43 million yuan [2]

| | | | 序号 | 姓名 | 职务 | | --- | --- | --- | | T | 简军 | 爱美客董事长 | | 2 | 赵燕 | 华熙生物董事长 | | 3 | 严建亚 | 巨子生物董事长 | | 4 | 关晓晖 | 复星医药联席董事长 | | 5 | 刘涛 | 奥园美谷节事长 | | 6 | 申东日 | 朗姿股份董事长 | | 7 | 杨貴 | 锦波生物青事长 | | 8 | 前熔 | 美年健康青事长 | | 9 | 傅海曙 | 瑞丽医美毒事长 | | 10 | (1) 郭振宇 | 贝泰妮董事长 | | | 榜单尚明:排名不分先后,围绕专业能力、业绩表现 行业11号 | | | | 响力等维度综合评选得出。 | | 2025年，在简军带领下，集团经营效率与盈利能力显著提升，加速拓展全球市场，技术储备丰富， 推"嗗科拉"等新品并拓展毛发健康、化妆品原料新赛道。 "2025年度医疗美容业十大杰出人物"榜单围绕专业能力、业绩表现、行业影响力等维度综合评选得出。 简军，1963年11月出生，清华大学工商管理硕士。1985年至1989年于中国粮油食品进出口总公司工作； 1990年至1995年于美国B ...

Investment Rating - The report rates the cosmetics and medical beauty industry as "Overweight" for 2025, indicating an expectation for the industry to outperform the overall market [2][11]. Core Insights - The demand side of the cosmetics and medical beauty sector is expected to accelerate, with retail sales of cosmetics projected to reach 465.3 billion yuan in 2025, a year-on-year growth of 5.1%, surpassing the overall retail growth by 1.4 percentage points [3]. - The performance of Hong Kong-listed beauty companies is strong, with significant growth in GMV (Gross Merchandise Volume) through platforms like Douyin, particularly during promotional events like Double Eleven [3]. - The A-share market shows a mixed performance, with companies like Ruoyuchen and Shanghai Jahwa experiencing substantial improvements in their earnings [3]. - The e-commerce operation sector is rebounding, with companies like Ruoyuchen and Yiwang Yichuang expected to see profit growth exceeding 50% in 2025 [3]. - The medical beauty segment is anticipated to face slight fatigue due to macroeconomic factors, but new product launches are expected to stimulate consumer interest in 2026 [3]. Summary by Sections Cosmetics Sector - Retail sales of cosmetics are projected to grow by 5.1% in 2025, with Q4 growth reaching 9.9% [3]. - Key companies such as Shiseido and Lin Qingxuan are expected to see significant GMV growth, with Lin Qingxuan projected to achieve triple-digit growth [3]. - Investment recommendations include companies with strong channel and brand matrices like Maogeping, Shiseido, and Lin Qingxuan, as well as those with improving earnings like Porlaia and Marubi [3]. Medical Beauty Sector - The medical beauty sector is expected to be impacted by macroeconomic conditions, with companies like Aimeike facing challenges [3]. - Recommendations focus on companies with strong R&D capabilities and broad product pipelines, such as Aimeike and Langzi [3]. E-commerce and Operations - The e-commerce operation sector is recovering, with companies like Ruoyuchen and Qingmu Technology expected to see significant profit growth [3]. - The report highlights the importance of self-operated brands and the potential for high growth in this segment [3]. Key Company Valuations - The report provides a valuation table for key companies, indicating a "Buy" rating for several firms including Porlaia, Maogeping, and Shiseido, with projected PE ratios reflecting growth expectations [5].

Market Overview - The medical beauty sector experienced a decline of 1.41% on January 27, with *ST Meigu leading the drop [1] - The Shanghai Composite Index closed at 4139.9, up 0.18%, while the Shenzhen Component Index closed at 14329.91, up 0.09% [1] Individual Stock Performance - Aimei Ke (300896) closed at 140.31, down 1.20% with a trading volume of 31,300 shares and a transaction value of 439 million [1] - Jinbo Biological (920982) closed at 228.34, down 1.31% with a trading volume of 5,531 shares and a transaction value of 127 million [1] - Huaxi Biological (688363) closed at 46.43, down 1.59% with a trading volume of 49,700 shares and a transaction value of 229 million [1] - *ST Meigu (000615) closed at 3.19, down 2.15% with a trading volume of 108,900 shares and a transaction value of 34.8 million [1] Capital Flow Analysis - The medical beauty sector saw a net outflow of 41.32 million from main funds and a net outflow of 3.13 million from speculative funds, while retail investors had a net inflow of 44.45 million [1] - For *ST Meigu, the main funds had a net outflow of 9.71 million, accounting for -27.91% of the total, while retail investors had a net inflow of 7.40 million, representing 21.26% [2] - Huaxi Biological experienced a net outflow of 14.32 million from main funds, with a net inflow of 4.64 million from retail investors [2] - Aimei Ke had a net outflow of 17.28 million from main funds, with a net inflow of 32.41 million from retail investors [2] - Jinbo Biological saw a net outflow of 19.33 million from main funds, with a net outflow of 188,440 from retail investors [2]

Group 1 - The core viewpoint of the article is that the company, Aimeike (300896), is actively managing its market value through a share repurchase plan amounting to 399 million yuan (excluding transaction costs) in 2023 [1] - The company emphasizes its commitment to market value management and will disclose any specific plans in accordance with relevant laws and regulations [1]

Group 1 - The medical beauty sector experienced a slight decline of 0.03% on January 26, with *ST Meigu leading the drop [1] - The Shanghai Composite Index closed at 4132.61, down 0.09%, while the Shenzhen Component Index closed at 14316.64, down 0.85% [1] - Key stocks in the medical beauty sector showed mixed performance, with Huaxi Biological up 1.03% and *ST Meigu down 1.81% [1] Group 2 - The medical beauty sector saw a net outflow of 14.71 million yuan from main funds, while retail investors contributed a net inflow of 8.53 million yuan [1] - Detailed fund flow data indicates that Huaxi Biological had a main fund net inflow of 5.91 million yuan, while *ST Meigu experienced a significant main fund net outflow of 7.46 million yuan [2] - Retail investors showed a positive net inflow in several stocks, with Love Beauty seeing a retail net inflow of 26.41 million yuan despite a main fund outflow [2]

Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry, indicating strong performance compared to the market [2]. Core Insights - The cosmetics and medical beauty sector has outperformed the market recently, with the Shenwan Beauty Care Index rising by 2.0% from January 16 to January 23, 2026, surpassing the Shenwan A Index by 0.8 percentage points [4][5]. - December 2025 saw a significant increase in social retail sales for cosmetics, reaching 38 billion yuan, with a growth rate of 8.8%, indicating robust demand even in the off-season. The overall growth rate for Q4 was 9.9%, significantly higher than the annual growth of 5.1% for 2025, driven by promotional events like Double 11 [10][17]. - The report anticipates continued high consumer demand in Q1 2026, supported by new product launches and regulatory approvals in the medical beauty sector [10]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector has shown strong performance, with the Shenwan Cosmetics Index increasing by 2.6% and the Shenwan Personal Care Index rising by 4.2%, both outperforming the Shenwan A Index [4][5]. Key Company Reviews - Lin Qingxuan (2657HK) is highlighted as a benchmark in the high-end domestic skincare market, with revenue projected to grow from 690 million yuan in 2022 to 1.21 billion yuan in 2024, representing a CAGR of 32.7%. The company is expected to turn a profit of 187 million yuan in 2024, a 120% increase year-on-year [11][12]. - Langzi Co., Ltd. (002612.SZ) forecasts a net profit of 900 million to 1.05 billion yuan for 2025, reflecting a year-on-year growth of 245.25% to 302.80% [4]. - Qingsong Co., Ltd. (300132.SZ) anticipates a net profit of 130 million to 165 million yuan for 2025, with a growth rate of 137.73% to 201.74% [4]. Market Trends - The report notes that the high-end skincare market is expanding, with the market size expected to reach 218.5 billion yuan by 2029. The concept of "oil-based skincare" is becoming mainstream, driving growth in the facial oil segment, which is projected to grow at a CAGR of 42.8% from 2019 to 2024 [12][14]. - E-commerce channels are increasingly important, with Lin Qingxuan achieving a 65.4% online revenue share in H1 2025, leveraging platforms like Douyin and Tmall for growth [13]. Sales Data - In December 2025, the total retail sales of cosmetics reached 38 billion yuan, with a year-on-year growth of 8.8%. The overall retail sales for cosmetics in 2025 were 465.3 billion yuan, reflecting a 5.1% increase [17][21].

Group 1 - The company emphasizes the importance of investor relations and adheres to laws and regulations regarding information disclosure [1] - The company commits to providing timely and objective responses to investor suggestions and inquiries [1]

Market Overview - The Shanghai Composite Index rose by 0.14% on January 22, with 22 out of the sectors in the Shenwan classification experiencing gains. The top-performing sectors were building materials and defense industry, with increases of 4.09% and 3.23% respectively [1] - Conversely, the beauty and personal care sector saw a decline of 0.76%, making it the worst-performing sector of the day [1] Capital Flow Analysis - The main capital flow showed a net outflow of 21.612 billion yuan across the two markets. However, 12 sectors experienced net inflows, with the telecommunications sector leading at a net inflow of 8.019 billion yuan and a daily increase of 2.83%. The defense industry followed with a net inflow of 5.713 billion yuan and a daily increase of 3.23% [1] - In contrast, 19 sectors faced net outflows, with the electronics sector experiencing the largest outflow of 13.206 billion yuan, followed by the power equipment sector with a net outflow of 7.206 billion yuan. Other sectors with significant outflows included non-ferrous metals, automotive, and pharmaceutical biotechnology [1] Beauty and Personal Care Sector - The beauty and personal care sector had a net outflow of 11.6 million yuan, with 29 stocks in the sector. Out of these, 9 stocks increased while 19 stocks decreased in value [2] - The stocks with the highest net inflows included Reliable Co., with a net inflow of 9.1418 million yuan, followed by Yanjiang Co. and Kesi Co., with net inflows of 8.6120 million yuan and 8.3405 million yuan respectively [2] - The stocks with the largest net outflows included Aimeike, Beitaini, and Qingdao Jinwang, with net outflows of 39.1013 million yuan, 32.7828 million yuan, and 22.1681 million yuan respectively [2] Individual Stock Performance - The top stocks in the beauty and personal care sector based on capital flow included: - Aimeike: -2.07% change with a net outflow of 39.1013 million yuan [2] - Beitaini: -1.42% change with a net outflow of 32.7828 million yuan [2] - Qingdao Jinwang: -0.85% change with a net outflow of 22.1681 million yuan [2] - Other notable stocks with significant capital flow included: - Reliable Co.: +1.62% change with a net inflow of 9.1418 million yuan [3] - Yanjiang Co.: -5.98% change with a net inflow of 8.6120 million yuan [3] - Kesi Co.: +1.29% change with a net inflow of 8.3405 million yuan [3]